Skip to main content

Table 1 Baseline patient demographics and clinical characteristics

From: Quality of life in children and adolescents with bipolar I depression treated with olanzapine/fluoxetine combination

Variable

OFC (N = 170)

Placebo (N = 85)

Total (N = 255)

Age (years), mean (SD)

14.6 (2.3)

15.0 (2.1)

14.7 (2.3)

Sex (male), n (%)

84 (49.4)

46 (54.1)

130 (51.0)

Race (white), n (%)

119 (70.0)

61 (71.8)

180 (70.6)

Ethnicity (hispanic), n (%)

38 (22.4)

23 (27.1)

61 (23.9)

BMI, kg/m2, mean (SD)

23.5 (5.54)

24.0 (5.81)

23.7 (5.62)

Number of previous episodes of depression, median (range)

2.0 (0.0–80.0)

2.0 (0.0–50.0)

2.0 (0.0–80.0)

CDRS-R total score, mean (SD)

54.6 (10.0)

53.7 (8.1)

54.3 (9.4)

YMRS total score, mean (SD)

6.1 (3.8)

6.2 (3.9)

6.1 (3.8)

CGI-BP overall severity, mean (SD)

4.4 (0.7)

4.3 (0.7)

4.4 (0.7)

  1. BMI body mass index, CDRS-R children’s depression rating scale-revised, CGI-BP clinical global impressions-bipolar, N number of patients, OFC olanzapine/fluoxetine combination, SD standard deviation, YMRS Young Mania Rating Scale